Literature DB >> 8841442

Quantitation of IgG subclass antibody responses after immunization with a group B meningococcal outer membrane vesicle vaccine, using monoclonal mouse-human chimeric antibodies as standards.

L M Naess1, E Rosenqvist, E A Høiby, T E Michaelsen.   

Abstract

An ELISA method was developed to quantitate gravimetrically (microgram/ml) the IgG subclass response against a Norwegian vaccine composed of outer membrane vesicles (OMV) isolated from a Neisseria meningitidis B:15:P1.7,16 epidemic strain. Chimeric mouse-human anti-hapten NIP (5-iodo-4-hydroxy-3-nitrophenacetyl) antibodies of each subclass were used for calibration purposes. Before vaccination, low amounts of IgG1 and IgG2 antibodies against OMV were detectable in all vaccinees, whereas IgG3 was only detectable in one of the 21 vaccinees. After vaccination, IgG1 antibodies dominated the response followed by IgG3 and low to moderate levels of IgG2 antibodies. IgG4 was only detectable at very low levels in a few vaccinees. All sera showed close to parallel dose-response curves to each other for IgG1 and IgG3, whereas the IgG2 curves were not parallel to chimeric IgG2 and could thus not be quantitated gravimetrically. For IgG3, 1/3 of the vaccinee sera showed non-parallel dose-response curves to the rest of the vaccinee sera and to chimeric IgG3 and could not be gravimetrically quantitated. The rest of the sera showed parallel dose-response curves with the chimeric IgG3 and gravimetric quantitation was possible. This study illustrates that chimeric antibodies can be used as calibrators to quantitate IgG subclass antibody responses against OMV in gravimetric units and that the vaccine mainly induces IgG1 and IgG3 antibodies in humans.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8841442     DOI: 10.1016/0022-1759(96)00108-1

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  6 in total

1.  Detection of complement-mediated antibody-dependent bactericidal activity in a fluorescence-based serum bactericidal assay for group B Neisseria meningitidis.

Authors:  K T Mountzouros; A P Howell
Journal:  J Clin Microbiol       Date:  2000-08       Impact factor: 5.948

2.  Human opsonins induced during meningococcal disease recognize outer membrane proteins PorA and PorB.

Authors:  A K Lehmann; A Halstensen; I S Aaberge; J Holst; T E Michaelsen; S Sornes; L M Wetzler; H Guttormsen
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

3.  Human T-cell responses after vaccination with the Norwegian group B meningococcal outer membrane vesicle vaccine.

Authors:  L M Naess; F Oftung; A Aase; L M Wetzler; R Sandin; T E Michaelsen
Journal:  Infect Immun       Date:  1998-03       Impact factor: 3.441

4.  Enhanced protective antibody to a mutant meningococcal factor H-binding protein with low-factor H binding.

Authors:  Dan M Granoff; Serena Giuntini; Flor A Gowans; Eduardo Lujan; Kelsey Sharkey; Peter T Beernink
Journal:  JCI Insight       Date:  2016-09-08

5.  Humoral immune responses to Neisseria meningitidis in children.

Authors:  A J Pollard; R Galassini; E M van der Voort; R Booy; P Langford; S Nadel; C Ison; J S Kroll; J Poolman; M Levin
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

6.  Comparison of Intranasal Outer Membrane Vesicles with Cholera Toxin and Injected MF59C.1 as Adjuvants for Malaria Transmission Blocking Antigens AnAPN1 and Pfs48/45.

Authors:  Michael Pritsch; Najib Ben-Khaled; Michael Chaloupka; Sebastian Kobold; Nicole Berens-Riha; Annabell Peter; Gabriele Liegl; Sören Schubert; Michael Hoelscher; Thomas Löscher; Andreas Wieser
Journal:  J Immunol Res       Date:  2016-04-27       Impact factor: 4.818

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.